Navigation Links
Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
Date:3/4/2009

WINSTON-SALEM, N.C. New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

An advance copy of the study appears online this week in the Journal of Neurology, the official publication of the European Neurological Society. It is scheduled to appear in a future print issue.

Prior to this study, physicians knew that administering intravenous immunoglobulin, or IVIg, could cause stroke or heart attack, but it was unclear when those serious side effects occurred.

"Stroke or heart attack has always been considered a fairly rare complication, but it's a catastrophic one," said James B. Caress, M.D., an associate professor of neurology and the study's lead researcher. Before this study, it was difficult for doctors to counsel patients about their risk for stroke or heart attack from IVIg treatment because previous reports could not identify which patients were at the highest risk, he added.

IVIg used in patients with autoimmune disorders, such as multiple sclerosis, and with immunodeficiencies is a drug made from human blood components. In patients who have an autoimmune disease, in which the body forms antibodies that attack its own tissues, IVIg can suppress the detrimental effects of those antibodies. In patients with advanced cancer, where the immune system is damaged from the tumor or chemotherapy, the drug boosts the immune system to stave off infections.

For the study, researchers looked at the medical records of 19 patients who had a stroke or heart attack after receiving IVIg. They also reviewed the records of 38 patients who were the same ages as those 19 patients, but who received IVIg treatment and did not have a stroke or heart attack. The patients, who had an average age of 71
'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Innovation for Battling Number One Killer in America Introduced by Eniva Nutraceutics
2. Select Comfort Launches Entirely Redesigned Line Of Sleep Number Beds
3. Record Number of Innovative New Medicines for Heart Disease and Stroke Now in Development
4. Joint Replacement Soars as Number of Docs Falls
5. Apollo Health Street Has Earned the Number One Spot in the BPO Healthcare Providers Segment in the Prestigious Black Book of Outsourcing Customer Satisfaction Survey, 2008
6. Alzheimers Association Releases Report That Predicts Doubling in Number of Californians With Neurological Disorder
7. Pre-verbal number sense common to monkeys, babies, college kids
8. U and CDC find startling numbers of active-military personnel engaging in frequent binge drinking
9. OnBase is the Choice for a Growing Number of Healthcare Organizations
10. Inspirational Dancers 50+ Prove Age is Just a Number
11. Increasing Number of Children Receive Pediatric Chiropractic Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Dr. Diane Walder, one of South ... to her practice called Ultrashape that is designed to help ... in just six weeks. Ultrashape has been praised by patients ... results when compared to other types of external fat reduction. ... said Dr. Walder. , According to Dr. Walder, Ultrashape ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Secura Consultants, based in Minneapolis, ... organizations in the country focused on delivering exemplary ... Secura Consultants is proud to offer complimentary Buy-Sell ... a leading global financial company. , Many businesses ... ownership interest comes the need for business succession ...
(Date:11/28/2014)... News) -- Celebration can quickly turn to tragedy ... experts say. Over the last decade, more than ... people were using turkey fryers, according to the U.S. ... for a patient who tried to deep fry the ... any circumstances," Dr. Arthur Sanford, a burn surgeon at ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... to determine how gender affects body,s reaction to HIV , ... may explain why HIV infection progresses faster to AIDS in ... say. , Their study found that a receptor molecule involved ... in women than in men. This then leads to differences ...
... , , , ... of St. Jude Children,s Research Hospital, has been invited to give ... , , The Leeuwenhoek Lecture, named ... the field of microbiology. Webster will present the lecture next summer. ...
... AURORA, Ohio, July 13 Arizona Cardinals 2008 NFC ... word to parents that vision problems can interfere with a child,s ... been told your child has perfect vision or 20/20 vision, your ... problem," warns Fitzgerald. , , Do ...
... tolerance to sudden hurts, , MONDAY, July 13 (HealthDay News) ... toe or experiencing some other painful incident? , Your ... , In a study that suggests bad words aren,t all ... hand in ice-cold water were able to withstand the frigid ...
... found that postmenopausal women who have taken a combined ... risk of developing progestin-accelerated breast tumors. Now, University of ... spice derived from the turmeric root, could reduce the ... therapy. "Approximately 6 million women in the United ...
... , , PARAMUS, N.J., July 13 Smart Balance, ... at www.smartbalance.com on August 6, 2009, at 9:30 ... at approximately 8:30 a.m. EDT the same day. The webcast will ... Investors and analysts may participate via conference call by dialing 1-800-895-0198 ...
Cached Medicine News:Health News:Immune Response May Speed AIDS Progression in Women 2Health News:St. Jude Virologist Honored by the Royal Society 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 3Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 4Health News:A Curse or Two Might Quell the Pain 2Health News:A Curse or Two Might Quell the Pain 3Health News:Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapy 2
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , a pharmaceutical ... of cancer, today announced that the University of ... institution, has successfully completed the first cohort in ... trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging ...
... 2012 HIGHLIGHTS :2012 Results (all ... Q1 2012 reported sales increased 5% to $665 million, a new ... Fine Chemicals ("SAFC") organic sales growth of 4% and 1%, respectively.  ... exchange rates reduced otherwise reportable sales by 2%. , ...
Cached Medicine Technology:Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 2Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 3Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 4Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....
Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Medicine Products: